title: Successful treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine.
abstract: Langerhans cell histiocytosis (LCH) is a rare disorder which frequently involves the lungs of affected adults. Recent evidence suggests it is a clonal neoplastic disorder. Prognosis in this disease is variable, but in its multisystem form or when associated with progressive respiratory dysfunction, prognosis is poor. Recent case reports and a phase II trial of the antimonocyte drug 2-chlorodeoxy-adenosine (2CDA) have described success in treating LCH. We used 2CDA to treat a young Australian man with LCH involving lungs and bone. A complete symptomatic remission was achieved with no evidence of recurrence some 5 years after completion of chemotherapy.
authors.affiliation: Royal Brompton Hospital, London, United Kingdom.
authors.forename: Nicole S L
authors.initials: NS
authors.lastname: Goh
authors.forename: Christine E
authors.initials: CE
authors.lastname: McDonald
authors.forename: Duncan P
authors.initials: DP
authors.lastname: MacGregor
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Pretto
authors.forename: Graeme N
authors.initials: GN
authors.lastname: Brodie
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001707:Biopsy, Needle; D017338:Cladribine / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D007262:Infusions, Intravenous; D008171:Lung Diseases / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D012129:Respiratory Function Tests; D012720:Severity of Illness Index; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D017338:Cladribine